Detalles de la búsqueda
1.
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
J Urol
; 182(5): 2195-203, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19758621
2.
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Eur Urol
; 60(3): 423-30, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21621906
3.
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Eur Urol
; 53(5): 992-1001, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17950987
4.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Eur Urol
; 52(5): 1398-406, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17485161
5.
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
J Urol
; 174(4 Pt 1): 1242-7, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16145378
Resultados
1 -
5
de 5
1
Próxima >
>>